Monash University: Bone Density Study
A study to prevent bone loss and
restore sexual function in women with
primary ovarian insufficiency
Melbourne and Perth
As many as 4 in every 100 Australian women go through menopause before the age of 40
years. This loss of ovarian function is called premature ovarian insufficiency (POI).
Women with POI do not produce sufficient estrogen or testosterone necessary for good
bone health. They experience progressive bone loss, increasing their risk of osteoporosis
(weakened bone strength) and fractures at a young age.
Despite adequate estrogen replacement many women with POI also experience sexual dysfunction.
There is some evidence that the addition of testosterone to estrogen replacement therapy
might prevent bone loss and restore sexual function in women with POI, but convincing
evidence from well conducted trials is needed.
The purpose of this research is to determine whether the use of testosterone therapy, in a
dose we have shown restores testosterone levels to those of premenopausal women,
prevents bone loss and improves sexual function in women with POI who are taking the
standard dose of oestrogen.
This is a 12-month study using topical testosterone cream applied to the skin on women aged under 45 years with primary ovarian insufficiency (complete loss of ovarian function before age 40).
Your participation would involve 5 visits with blood collection and bone density scans
To participate or for further information
Please contact:
Women’s Health Research Program
Monash University
Phone: (03) 99030827
Email: womens.health@monash.edu
The Women’s Health Research Program
Latest News
The Female Sexual Response—It’s Not Just About Spontaneous Desire
The Female Sexual Response—It’s Not Just About Spontaneous Desire Sexual desire in women often follows a different path than we expect. According to the Basson… Continue Reading →
In Australia, is Addyi (Flibanserin) available or what is available?
Australia Leads the Way in Androgen Treatment for Women with HSDD While the US-approved drug flibanserin offers limited benefit for Hypoactive Sexual Desire Disorder (HSDD), it’s… Continue Reading →
How Satisfied are you with Your Sex Life?
Let’s Talk About Sexual Satisfaction—It Matters More Than You Think Did you know that 4 in 10 women experience sexual concerns during mid-life? Yet many suffer… Continue Reading →